-
Top 10 Biotech Jobs Most in Demand over the Next Decade
Which Occupations Are Most Likely to See Job Growth by 2026?
-
Why Cardiology Is the Next Frontier for Precision Medicine
Cardiovascular Disease Applications Are Set to Focus on Highly Individualized Variables for Therapy
-
Supplement: Cancer Immunotherapies Development Barriers
Current State of Protocol Design Impacting Small to Mid-Sized Biotech Companies
-
True CRISPR: A Genetic Genre with Novel Twists
With Multiplexing, Nanodelivery, and Other Advances, CRISPR Reality Outstrips CRISPR Fiction
GEN Contributor
Sue Pearson Ph.D.
Sue Pearson, Ph.D., is a freelance writer for GEN.
More GEN Content From This Contributor
- Feature Articles: Therapeutic Cancer Vaccine Options
- Feature Articles: Embryonic Stem Cells: Not Just From Humans
- Feature Articles: BioSimilars Market Ripe for Expansion
- Feature Articles: Producing Biologics Less Expensively
- Feature Articles: Boosting Use of Microbial Systems in Manufacturing
- Feature Articles: Advancing Cancer Vaccines
- Feature Articles: Funding Issues Stymie Pandemic Preparation
- Feature Articles: Superbugs vs. Superdrugs: Race Goes On
- Feature Articles: Managing Asthma and COPD Treatments
- Feature Articles: Is the U.K. Biotech Industry on the Skids?
- Feature Articles: Spain Invests in Quest for Big Biotech Payoff
- Feature Articles: Investigating and Focusing on Ion Channels as Drug Targets
- Feature Articles: Big Pharma's Interest in Vaccine Products on Rise
- Feature Articles: Adoption of Label-Free Technologies Surges
- Feature Articles: Cell Therapy Building on Momentum
- Feature Articles: Central Eastern Europe Targets Biotech
- Feature Articles: Epigenetic-Derived Therapies on Horizon
- Feature Articles: U.K. Works to Keep Its Edge
- Feature Articles: Discovery Aided by Complex Assays
- Feature Articles: Single-Use Systems Drive Down Costs
- Feature Articles: U.K. Biopharma Bouncing Back
- Columns: Working Toward Better, Cheaper Drug Discovery
- Columns: EMD Millipore Takes European Roadtrip
- Feature Articles: Regen Med Nears the Market
- GEN Exclusives: Open Innovation in the Pharma Industry
- Feature Articles: Where Downstream Operations Are Headed
- GEN Exclusives: Poland Invests in Biotech Infrastructure
- GEN Exclusives: Can the U.K. Maintain Its Biomanufacturing Empire?
- GEN Exclusives: Implementing a Full Quality-by-Design Strategy
- GEN Exclusives: Driving Down the Cost of Stem Cell Manufacturing
- GEN Exclusives: U.K. Continues to Invest in GMP Manufactured Biologics and Advanced Therapies
- GEN Exclusives: Smart Process Development Strategies
- Columns: U.K. Aims at $15B Gene Therapy Industry
- Columns: U.K. Bioindustry Plots Its Post-Brexit Course
- GEN Exclusives: Translating Innovation into Therapies
- GEN Exclusives: Will Cell and Gene Therapies Reach a Tipping Point?
- GEN Exclusives: Screening Innovations and 3D Cell Culture Assay Developments Showcased at ELRIG
- GEN Exclusives: UK Biotechs Present Novel Technologies at BioTrinity 2017
- GEN Exclusives: Why is Adaptive Manufacturing of Biologics Difficult?
